Loading
Myriad Genetics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 May 2026.
Myriad Genetics Inc: what insiders have been doing
Headquartered in Salt Lake City, United States, Myriad Genetics Inc belongs to the Healthcare & Pharma sector and traces its origins to 1992. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 32 filings came from 14 insiders.
No insider sold shares on the market over the period. Instead, the filings list 3 purchases totalling €222k, made by 3 insiders. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 2 senior executives and 1 chief executive. Raha Samraat S. filed the largest purchase, €173k, on 9 March 2026.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 32 filings here. Since 2021, the database holds 3 purchases and 25 sales by insiders of the company. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 824.5 m USD and net income at -365.9 m USD.
Within a 30-day window, 1 purchase overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 14 May 2026, 157 days ago. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
316
Thresholds
n/a
Buy Volume
€221,659
3 ops. · all time
Sell Volume
€7M
25 ops. · all time
Who traded when
BuySalePaul Bisaro1 buy
S. Louise Phanstiel1 buy
Samraat S. Raha1 buy
Since the insiders bought
- +14.0%Entry US$3.58 · Close 13 Oct 2026 US$4.08
- -14.3%Entry US$5.12 · Close at T+90 US$4.39
- -20.8%Entry US$5.01 · Close at T+90 US$3.97
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Myriad Genetics Inc Hold (neutral), based on 8 analysts. Average price target: US$4.05.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,649 of 24,148 companies
22.6
score / 100
Value12
Quality33
FCF yld-6.2%
Earn yld-88%
EV/EBITDA·
ROE-33%
Gross mgn70%
Net mgn-44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.20
Analyst consensus
8 analystsHold
US$2.00Target US$4.05(-4%)US$8.00
Income statement
RevenueUS$824.5M
Gross profitUS$576.6M70% margin
EBITDA-US$330.9M-40% margin
Net income-US$365.9M-14.0% margin
Valuation
PER (forward)-7.1x
P/Book1.3x
Beta1.64
Balance sheet & cash
Market capUS$401.7M
Total debtUS$209.8M
Free Cash Flow-US$25.6M
Debt / Equity69%
Profitability & ownership
ROE-32.5%
ROA-8.6%
% insiders4.0%
% institutions97.1%
Last declaration on 22 September 2026
Declarations316 total
2,555 shares@ US$4.010.0026% mcap17.5% of flowCommon StockSEC:0002082246-26-000010:0
257,731 shares0Common StockSEC:0001931406-26-000007:0
4,398 shares@ US$3.230.0035% mcap32.1% of flowCommon StockSEC:0001914879-26-000004:0
8,761 shares@ US$3.030.0066% mcap44.9% of flowCommon StockSEC:0002082246-26-000008:0
15,000 shares@ US$4.590.023% mcap24.0% of flowCommonSEC144:0001959173-26-004408
59,701 shares0Common StockSEC:0002024613-26-000002:0
59,701 shares0Common StockSEC:0001237253-26-000004:0
59,701 shares0Common StockSEC:0001379372-26-000002:0
7,500 shares@ US$3.6850.0070% mcap100.0% of flowCommon StockSEC:0001237253-26-000002:0
Canonical exit: 12 Aug 2026 (T+90)
1,069 shares@ US$4.910.0017% mcap0.5% of flowCommon StockSEC:0001517026-26-000008:0
946 shares@ US$4.910.0015% mcap1.7% of flowCommon StockSEC:0001922964-26-000010:0
2,019 shares@ US$4.583.5% of flowCommon StockSEC:0001922964-26-000008:0
549 shares@ US$4.584.3% of flowCommon StockSEC:0002082246-26-000006:0
2,055 shares@ US$4.580.9% of flowCommon StockSEC:0001517026-26-000006:0
226,804 shares0Common StockSEC:0002065630-26-000002:0
173,196 shares0Common StockSEC:0001922964-26-000006:0
247,423 shares0Common StockSEC:0001517026-26-000004:0
173,196 shares0Common StockSEC:0001472827-26-000004:0
6,412 shares@ US$4.666.1% of flowCommon StockSEC:0001843872-26-000005:0
206,186 shares0Common StockSEC:0002082246-26-000004:0
195,876 shares0Common StockSEC:0001914879-26-000002:0
618,557 shares0Common StockSEC:0001738340-26-000004:0
40,000 shares@ US$4.996122.1% of flowCommon StockSEC:0001738340-26-000002:0
Canonical exit: 7 Jun 2026 (T+90)
1,675 shares@ US$4.6113.3% of flowCommon StockSEC:0001472827-26-000002:0
6,100 shares@ US$4.7363.7% of flowCommon StockSEC:0001471518-26-000002:0
Canonical exit: 26 May 2026 (T+90)
25 of 316 declarations
About Myriad Genetics Inc
Myriad Genetics Inc. is a U.S.-based molecular diagnostics and precision medicine company listed on the NASDAQ under the ticker MYGN, in the United States. Founded in the 1990s and historically rooted in Salt Lake City, Utah, Myriad has built a long-standing reputation as a science-led diagnostics provider focused on using genetic information to guide disease risk assessment, diagnosis, prognosis and treatment selection. Its business model is centered on proprietary laboratory testing, clinical evidence generation and deep engagement with healthcare providers. Management has said the company served more than 55,000 healthcare providers and delivered more than 1.5 million molecular diagnostic and precision medicine test results in 2025, underscoring a meaningful commercial footprint. ([myriad.com](https://myriad.com/about-myriad/myriad-around-the-world/?utm_source=openai))
The company’s revenue base is organized around four core categories: Hereditary Cancer, Tumor Profiling / Oncology, Prenatal and Mental Health. In hereditary cancer, flagship products include MyRisk and BRACAnalysis CDx. In oncology, Myriad markets MyChoice CDx, Prolaris, Precise Tumor and EndoPredict. In prenatal health, the main offerings include Foresight, Prequel, FirstGene and SneakPeek. In mental health, GeneSight remains the key pharmacogenomics platform. Myriad also participates in companion diagnostics and pharmaceutical partnerships, aiming to embed its tests into clinical workflows and treatment-development programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000899923/000089992326000018/mygn-20251231.htm?utm_source=openai))
Read moreShow less
From a historical perspective, Myriad is one of the sector’s better-known pioneers. The company states that it helped discover the BRCA1/2 genes, launched BRACAnalysis in 1996, and developed one of the first prognostic tests for prostate cancer. That scientific heritage remains an important competitive asset. The company competes in a crowded diagnostics market against specialized molecular testing peers and larger healthcare groups with significant scale, R&D budgets and commercial reach. Myriad’s differentiation comes from clinical utility, brand recognition, proprietary data and a broad installed base of ordering physicians rather than from commoditized testing alone. ([myriad.com](https://myriad.com/about-myriad/myriad-around-the-world/?utm_source=openai))
Geographically, Myriad is still primarily exposed to the U.S. market, with its headquarters and major support operations in Salt Lake City, Utah, while maintaining selective international operations. Recent strategic milestones matter for investors. In 2024, the company acquired selected assets from Intermountain Precision Genomics, including Precise Tumor and Precise Liquid. In 2025, it announced a strategic collaboration with PATHOMIQ to add AI technology to its oncology portfolio, and a separate collaboration with SOPHiA GENETICS to develop a liquid-biopsy companion diagnostic offering. In 2026, Myriad outlined a more focused strategy centered on the Cancer Care Continuum, with planned product launches including Precise MRD, an AI-enabled Prolaris version and FirstGene. ([investor.myriad.com](https://investor.myriad.com/news-releases/news-release-detail/26041/?utm_source=openai))
